Chitosan-based nanostructures: A delivery platform for ocular therapeutics

被引:285
作者
de la Fuente, Maria [2 ]
Ravina, Manuela [1 ]
Paolicelli, Patrizia [1 ]
Sanchez, Alejandro [1 ]
Seijo, Begona [1 ]
Jose Alonso, Maria [1 ]
机构
[1] Univ Santiago de Compostela, Dept Pharm & Pharmaceut Technol, Fac Pharm, Santiago De Compostela 15782, Spain
[2] Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1 1AX, England
关键词
Chitosan; Ocular; Ophthalmics; Drug delivery; Gene delivery; Hyaluronan; Nanocapsules; Nanoparticles; Nanostructures; Emulsions; OPHTHALMIC DRUG-DELIVERY; NONVIRAL GENE DELIVERY; CHARGED SUBMICRON EMULSION; RETINAL-PIGMENT EPITHELIUM; CORNEAL ENDOTHELIAL-CELLS; IN-VITRO; HYALURONIC-ACID; ANTISENSE OLIGONUCLEOTIDES; DNA NANOPARTICLES; CYCLOSPORINE-A;
D O I
10.1016/j.addr.2009.11.026
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Nanoscience and nanotechnology has caused important breakthroughs in different therapeutic areas. In particular, the application of nanotechnology in ophthalmology has led to the development of novel strategies for the treatment of ocular disorders. Indeed, the association of an active molecule to a nanocarrier allows the molecule to intimately interact with specific ocular structures, to overcome ocular barriers and to prolong its residence in the target tissue. Over the last decade, our group has designed and developed a delivery platform based on the polysaccharide chitosan, which suits the requirements of the topical ocular route. These nanosystems have been specifically adapted for the delivery of hydrophilic and lipophilic drugs and also polynucleotides onto the eye surface. The results collected up until now suggest the potential of this delivery platform and the subsequent need of a full preclinical evaluation in order to satisfy the specific regulatory demands of this mode of administration. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:100 / 117
页数:18
相关论文
共 202 条
[1]
Abdulrazik M, 2001, STP PHARMA SCI, V11, P427
[2]
Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system [J].
Aggarwal, D ;
Kaur, IP .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 290 (1-2) :155-159
[3]
DISPOSITION OF TIMOLOL AND INULIN IN THE RABBIT EYE FOLLOWING CORNEAL VERSUS NON-CORNEAL ABSORPTION [J].
AHMED, I ;
PATTON, TF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1987, 38 (1-3) :9-21
[4]
Challenges and solutions in topical ocular drug- delivery systems [J].
Ali, Maryam ;
Byrne, Mark Edward .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2008, 1 (01) :145-161
[5]
The potential of chitosan in ocular drug delivery [J].
Alonso, MJ ;
Sánchez, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (11) :1451-1463
[6]
High throughput solubility measurement in drug discovery and development [J].
Alsenz, Jochem ;
Kansy, Manfred .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :546-567
[7]
[Anonymous], 1992, STP PHARMA SCI
[8]
Aragona P, 2004, CHEMISTRY AND BIOLOGY OF HYALURONAN, P529
[9]
EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].
ARTURSSON, P ;
LINDMARK, T ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361
[10]
Chitosan based nanocarriers for indomethacin ocular delivery [J].
Badawi, Alia A. ;
El-Laithy, Hanan M. ;
El Qidra, Riad K. ;
El Mofty, Hala ;
El Dally, Mohamed .
ARCHIVES OF PHARMACAL RESEARCH, 2008, 31 (08) :1040-1049